<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Med Res</journal-id><journal-id journal-id-type="iso-abbrev">Eur. J. Med. Res</journal-id><journal-title-group><journal-title>European Journal of Medical Research</journal-title></journal-title-group><issn pub-type="ppub">0949-2321</issn><issn pub-type="epub">2047-783X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20156747</article-id><article-id pub-id-type="pmc">3521372</article-id><article-id pub-id-type="publisher-id">2047-783X-14-S4-151</article-id><article-id pub-id-type="doi">10.1186/2047-783X-14-S4-151</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Sympathetic hyperactivity influences chemosensor function in patients with end-stage renal disease</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Meyer</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Christian.Meyer@med.uni-duesseldorf.de</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Schueller</surname><given-names>P</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Balzer</surname><given-names>J</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Lauer</surname><given-names>T</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Westenfeld</surname><given-names>R</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Schauerte</surname><given-names>P</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Hennersdorf</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Steiner</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Kelm</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Rassaf</surname><given-names>T</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Division of Cardiology, Pulmonology and Angiology, University of Duesseldorf</aff><aff id="I2"><label>2</label>Division of Cardiology and Pulmonology, RWTH Aachen University</aff><aff id="I3"><label>3</label>Medical Clinic I, SLK-Kliniken Heilbronn, Germany</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>7</day><month>12</month><year>2009</year></pub-date><volume>14</volume><issue>Suppl 4</issue><supplement><named-content content-type="supplement-title">International Conference 'Advances in Pneumology&#x02019;</named-content><named-content content-type="supplement-editor">Mieczyslaw Pokorski, Adrian Gillissen, Kurt Rasche</named-content></supplement><fpage>151</fpage><lpage>155</lpage><permissions><copyright-statement>Copyright &#x000a9;2009 I. Holzapfel Publishers</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>I. Holzapfel Publishers</copyright-holder></permissions><self-uri xlink:href="http://www.eurjmedres.com/content/14/S4/151"/><abstract><sec><title>Background</title><p>Autonomic neuropathy is common in patients suffering from end-stage renal disease (ESRD). This may in part explain the high cardiovascular mortality in these patients. Chemosensory function is involved in autonomic cardiovascular control and is mechanistically linked to the sympathetic tone.</p></sec><sec><title>Objective</title><p>The aim of the present study was to assess whether sympathetic hyperactivity contributes to an altered chemosensory function in ESRD.</p></sec><sec><title>Materials and methods</title><p>In a randomized, double-masked, placebo controlled crossover design we studied the impact of chemosensory deactivation on heart rate, blood pressure and oxygen saturation in 10 ESRD patients and 10 age and gender matched controls. The difference in the R-R intervals divided by the difference in the oxygen pressures before and after deactivation of the chemoreceptors by 5-min inhalation of 7 L oxygen was calculated as the hyperoxic chemoreflex sensitivity (CHRS). Placebo consisted of breathing room air. Baseline sympathetic activity was characterized by plasma catecholamine levels and 24-h time-domain heart rate variability (HRV) parameters.</p></sec><sec><title>Results</title><p>Plasma norepinephrine levels were increased (1.6 &#x000b1; 0.4 vs. 5.8 &#x000b1; 0.6; P &#x0003c; 0.05) while the SDNN (standard deviation of all normal R-R intervals: 126.4 &#x000b1; 19 vs. 100.2 &#x000b1; 12 ms), the RMSSD (square root of the mean of the squared differences between adjacent normal R-R intervals: 27.1 &#x000b1; 8 vs. 15.7 &#x000b1; 2 ms), and the 24-h triangular index (33.6 &#x000b1; 4 vs. 25.7 &#x000b1; 3; each P &#x0003c; 0.05) were decreased in ESRD patients as compared to controls. CHRS was impaired in ESRD patients (2.9 &#x000b1; 0.9 ms/mmHg, P &#x0003c; 0.05) as compared to controls (7.9 &#x000b1; 1.4 ms/mmHg). On multiple regression analysis 24 h-Triangular index, RMSSD, and plasma norepinephrine levels were independent predictors of an impaired hyperoxic CHRS.</p></sec><sec><title>Conclusion</title><p>Sympathetic hyperactivity influences chemosensory function in ESRD resulting in an impaired hyperoxic CHRS.</p></sec></abstract><kwd-group><kwd>chemoreflexes</kwd><kwd>end-stage renal disease</kwd><kwd>nervous system</kwd><kwd>sympathetic</kwd></kwd-group><conference><conf-date>12-14 June 2009</conf-date><conf-name>International Conference 'Advances in Pneumology&#x02019;</conf-name><conf-loc>Leipzig, Germany</conf-loc></conference></article-meta></front><body><sec><title>Introduction</title><p>Autonomic neuropathy is common in patients with end-stage renal disease (ESRD). This may in part explain the high cardiovascular mortality in these patients [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B4">4</xref>]. The underlying mechanisms of a sympathetic-parasympathetic imbalance in ESRD are still not fully understood. Previous reports demonstrated that sympathetic activation in ESRD involves firing of afferent renal nerve fibres, activation of the renin-angiotensin system, and decreased nitric oxide bioavailability [<xref ref-type="bibr" rid="B5">5</xref>]. A causal link between tonic chemoreflex activation and an increased efferent sympathetic activity to muscle circulation has recently been reported [<xref ref-type="bibr" rid="B6">6</xref>].</p><p>Deactivation of peripheral chemosensors by inhalation of pure oxygen, leads to sympathetic withdrawal and a subsequent decrease of heart rate [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. Impairment of this desensitization, as a consequence of tonic chemoreflex activation, has been demonstrated to be a predictor of ventricular tachyarrhythmias. The hyperoxic cardiac chemoreflex sensitivity (CHRS) reflects the relative decrease of R-R intervals during administration of concentrated O<sub>2 </sub>and characterizes the deactivation of carotid and/or aortic chemoreceptors. The aim of the present study was to assess whether sympathetic hyperactivity influences chemosensory function in ESRD.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><sec><title>Study Design</title><p>The study was approved by a local Ethics Committee. In a randomized, double-masked, placebo controlled crossover design we studied the impact of chemosensory deactivation on heart rate, blood pressure, and oxygen saturation by 5-min inhalation of 100% oxygen in 10 ESRD patients and 10 age and gender matched controls. We assessed whether the resting sympathetic tone, as measured by baseline plasma catecholamine levels and time-domain heart rate variability (HRV) parameters, contributes to chemosensory activation in ESRD resulting in an impaired hyperoxic CHRS. Placebo consisted of breathing room air.</p></sec><sec><title>Patients</title><p>Patients with ESRD (21 - 80 years) who had been on chronic hemodialysis for at least 6 months were investigated. Other cardiovascular risk factors and pre-existing cardiovascular disease did not preclude from participation in the study. Exclusion criteria were congestive heart failure with a cardiac ejection fraction of &#x0003c; 35%, acute inflammation (C-reactive protein &#x0003e; 5 mg/l), chronic pulmonary diseases, diabetes mellitus, neurocardiogenic syncope, sleep apnoea syndrome, hyperthyroidism, and heart rhythm other than sinus (Table <xref ref-type="table" rid="T1">1</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Baseline characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="left">Controls<break/>(n = 10)</th><th align="left">ESRD<break/>(n = 10)</th></tr></thead><tbody><tr><td align="left">Age, yr</td><td align="left">62 &#x000b1; 6</td><td align="left">65 &#x000b1; 4</td></tr><tr><td align="left">Male sex, n</td><td align="left">6</td><td align="left">6</td></tr><tr><td align="left">Hx hypertension, n</td><td align="left">7</td><td align="left">7</td></tr><tr><td align="left">Hx dyslipidemia, n</td><td align="left">8</td><td align="left">7</td></tr><tr><td align="left">Hx smoking, n</td><td align="left">6</td><td align="left">5</td></tr><tr><td align="left">Hx CAD, n</td><td align="left">5</td><td align="left">4</td></tr><tr><td align="left">Hx CVD, n</td><td align="left">4</td><td align="left">1</td></tr><tr><td align="left">Hemoglobin, g/l</td><td align="left">132 &#x000b1; 7</td><td align="left">126 &#x000b1; 4</td></tr><tr><td align="left" colspan="3"><bold>Medication, n (%)</bold></td></tr><tr><td align="left">&#x02003;Alpha-blockers</td><td align="left">3</td><td align="left">1</td></tr><tr><td align="left">&#x02003;Beta-blockers</td><td align="left">6</td><td align="left">5</td></tr><tr><td align="left">&#x02003;ACE-inhibitors/AT-II-antagonists</td><td align="left">6</td><td align="left">6</td></tr><tr><td align="left">&#x02003;Calcium antagonists</td><td align="left">5</td><td align="left">2</td></tr><tr><td align="left">&#x02003;Central sympatholytic agents</td><td align="left">0</td><td align="left">2</td></tr><tr><td align="left">&#x02003;Isosorbide dinitrate</td><td align="left">3</td><td align="left">1</td></tr><tr><td align="left">&#x02003;Diuretics</td><td align="left">7</td><td align="left">5</td></tr><tr><td align="left">&#x02003;Statins</td><td align="left">7</td><td align="left">5</td></tr></tbody></table><table-wrap-foot><p>Hx, indicates history of; CAD, coronary artery disease; CVD, cerebrovascular disease; Values are means &#x000b1; SE.</p></table-wrap-foot></table-wrap></sec><sec><title>Measurements of Heart Rate, Blood Pressure, Standard Clinical Blood Parameters, and Sympathetic Activity</title><p>Blood pressure was measured non-invasively with a sphygmomanometer cuff. Blood was drawn after a 30 min resting period through large-bore angiocatheters (18 gauge) to prevent artefact hemolysis. The first 3 ml of blood was discarded, and the blood then slowly drawn into prechilled tubes. Standard clinical blood parameters including renal function were immediately analyzed in a central laboratory using standard techniques [<xref ref-type="bibr" rid="B8">8</xref>]. Plasma norepinephrine and epinephrine were quantified by high-performance liquid chromatography. The tubes were kept on ice until centrifugation at 4&#x000b0;C. Plasma samples were stored at -70&#x000b0;C until assayed. Heart rate was measured continuously by a 12-channel electrocardiogram (ECG). Additionally, the mean R-R interval was calculated from 10 consecutive R-R intervals. HRV time-domain measures were determined from an ambulatory 24-h ECG in the day without hemodialysis in order to avoid the influence of the hemodialysis session on HRV parameters. The following HRV parameters, which are considered to be standardized in the general population, were calculated for each patient to characterize cardiac sympathetic-parasympathetic control: (i) the 24-h SD of normal R-R intervals (SDNN, ms), as a global measure of HRV; (ii) The SD of the average normal R-R interval for all 5-min segments of a 24-h ECG recording (SDANN, ms); and (iii) the square root of the mean of the squared differences between adjacent normal R-R intervals (RMSSD, ms); (iv) The Triangular index, a time-domain geometric measure.</p></sec><sec><title>Chemosensory Deactivation</title><p>To characterize the effect of chemosensory deactivation on heart rate, blood pressure, and oxygen saturation, we determined the venous partial oxygen pressure (pO<sub>2</sub>), before and after breathing oxygen and room air, respectively, via a nose mask. Baseline measurements were taken after patients were recumbent for a period of 10 min. Pure oxygen or room air was then administered via a nose mask for 5 min. Following a 30-min recovery, the identical protocol (10 min of baseline followed by a double-blinded administration of either 100% oxygen or room air via a nose mask) was repeated.</p><p>Oxygen saturation was monitored with a pulse oximeter. Partial oxygen pressure was determined using a blood gas analyser (Radiometer Copenhagen). Conversation was only allowed during the 30-min recovery in order to minimize mental influences. The difference in the R-R intervals in the ECG before and after inhalation of pure oxygen divided by the difference in the oxygen pressures were calculated as the CHRS [ms/mmHg]. A CHRS below 3.0 ms/mm Hg was defined as pathological as reported earlier [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. Measurements were performed after an overnight fasting period in a noise protected room of constant temperature.</p></sec><sec><title>Statistical Analysis</title><p>After testing for normal distribution, group comparisons were calculated using Student t tests or Mann-Whitney U-tests for continuous variables as appropriate. Categorical data were analysed by Chi<sup>2 </sup>with Fisher's exact test. Correlations were determined with regression (r) analysis coefficient. Multivariate analysis for CHRS prediction was assessed using a multiple regression model. Data are presented as means &#x000b1; SEM for continuous variables or as a percentage of patients for categorical variables. A two-sided P &#x0003c; 0.05 was considered significant. Statistical analysis was done with SPSS software for windows version 14.0 (SPSS, Chicago, IL). This trial is registered with ClinicalTrials.gov, number NCT00794872.</p></sec></sec><sec sec-type="results"><title>Results</title><p>Age, gender, cardiovascular risk factors, or concomitant drug therapy did not differed between the control and ESRD subjects (Table <xref ref-type="table" rid="T1">1</xref>). ESRD resulted from nephrosclerosis (n = 1), polycystic kidney disease (n = 2), suspected glomerulonephritis (n = 2), and hypertensive/vascular renal damage (n = 5). The average dialysis vintage was 26 &#x000b1; 9 months. None of the patients had received blood transfusions during the preceding 6 months. Plasma norepinephrine levels were significantly higher in ESRD patients and time-domain HRV parameters indicated a relative predominance of sympathetic activation in ESRD (Table <xref ref-type="table" rid="T2">2</xref>).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Sympathetic tone, as measured by baseline plasma catecholamine levels and 24-h heart rate variability, in endstage renal disease (ESRD) patients and controls.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="center">Controls<break/>(n = 10)</th><th align="center">ESRD<break/>(n = 10)</th></tr></thead><tbody><tr><td align="left">Plasma catecholamine levels</td><td/><td/></tr><tr><td align="left">&#x02003;Norepinephrine, nmol/L</td><td align="center">1.6 &#x000b1; 0.4</td><td align="center">5.8 &#x000b1; 0.6*</td></tr><tr><td align="left">&#x02003;Epinephrine, pmol/L</td><td align="center">342 &#x000b1; 75</td><td align="center">742 &#x000b1; 281</td></tr><tr><td align="left" colspan="3">Heart rate variability</td></tr><tr><td align="left">&#x02003;SDNN, ms</td><td align="center">126.4 &#x000b1; 19</td><td align="center">100.2 &#x000b1; 12*</td></tr><tr><td align="left">&#x02003;SDANN, ms</td><td align="center">121 &#x000b1; 20</td><td align="center">95.7 &#x000b1; 10</td></tr><tr><td align="left">&#x02003;RMSSD, ms</td><td align="center">27.1 &#x000b1; 8</td><td align="center">15.7 &#x000b1; 2*</td></tr><tr><td align="left">&#x02003;Triangular index</td><td align="center">33.6 &#x000b1; 4</td><td align="center">25.7 &#x000b1; 3*</td></tr></tbody></table><table-wrap-foot><p>Values are means &#x000b1; SEM. *P &#x0003c; 0.05.</p></table-wrap-foot></table-wrap><sec><title>Chemosensory Deactivation</title><p>None of the patients were hypoxemic at baseline or after oxygen inhalation, with oxygen saturation values ranging from 96% to 100%. Baseline oxygen saturation and heart rate in patients with ESRD were not significantly different from those observed in controls. After chemoreflex deactivation by inhalation of 100% oxygen the venous pO<sub>2 </sub>of all subjects increased from 34 &#x000b1; 2 mmHg to 65 &#x000b1; 2 mmHg (P &#x0003c; 0.001) resulting in an increased R-R interval (936.9 &#x000b1; 19.9 ms vs. 974.9 &#x000b1; 23.3 ms; P &#x0003c; 0.001). After room air administration pO<sub>2 </sub>and heart rate did not change in ESRD patients (Table <xref ref-type="table" rid="T3">3</xref>) or controls (Table <xref ref-type="table" rid="T4">4</xref>) but differed from the values obtained after chemosensory deactivation (P &#x0003c; 0.05) indicating a tonic chemosensory activation in ESRD.</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Effects of 100% oxygen and room air administration in end-stage renal disease patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="center" colspan="2">100% oxygen</th><th align="center" colspan="2">Room air</th></tr><tr><th/><th align="center">Before</th><th align="center">After</th><th align="center">Before</th><th align="center">After</th></tr></thead><tbody><tr><td align="left">Heart rate, bpm</td><td align="center">70 &#x000b1; 2</td><td align="center">67 &#x000b1; 2*</td><td align="center">68 &#x000b1; 3</td><td align="center">67 &#x000b1; 2</td></tr><tr><td align="left">R-R interval, ms</td><td align="center">929 &#x000b1; 8</td><td align="center">970 &#x000b1; 29*</td><td align="center">882 &#x000b1; 9</td><td align="center">895 &#x000b1; 10</td></tr><tr><td align="left">PO<sub>2</sub>, mmHg</td><td align="center">33.1 &#x000b1; 3.8</td><td align="center">50.8 &#x000b1; 5.5*</td><td align="center">32.7 &#x000b1; 2.9</td><td align="center">33.1 &#x000b1; 3.2</td></tr><tr><td align="left">Oxygen saturation, %</td><td align="center">97 &#x000b1; 1</td><td align="center">98 &#x000b1; 1</td><td align="center">97 &#x000b1; 1</td><td align="center">97 &#x000b1; 1</td></tr><tr><td align="left">MAP, mmHg</td><td align="center">91 &#x000b1; 3</td><td align="center">89 &#x000b1; 2</td><td align="center">94 &#x000b1; 2</td><td align="center">93 &#x000b1; 3</td></tr></tbody></table><table-wrap-foot><p>*P &#x0003c; 0.05 vs. before oxygen administration. Values are means &#x000b1; SEM.</p></table-wrap-foot></table-wrap><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Effects of 100% oxygen and room air administration in controls.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="center" colspan="2">100% oxygen</th><th align="center" colspan="2">Room air</th></tr><tr><th/><th align="center">Before</th><th align="center">After</th><th align="center">Before</th><th align="center">After</th></tr></thead><tbody><tr><td align="left">Heart rate, bpm</td><td align="center">65 &#x000b1; 3</td><td align="center">62 &#x000b1; 2*</td><td align="center">65 &#x000b1; 2</td><td align="center">64 &#x000b1; 2</td></tr><tr><td align="left">R-R interval, ms</td><td align="center">940 &#x000b1; 31</td><td align="center">983 &#x000b1; 37*</td><td align="center">860 &#x000b1; 19</td><td align="center">860 &#x000b1; 19</td></tr><tr><td align="left">PO<sub>2</sub>, mmHg</td><td align="center">36.5 &#x000b1; 2.5</td><td align="center">43.9 &#x000b1; 2.8*</td><td align="center">35.7 &#x000b1; 2.4</td><td align="center">36.2 &#x000b1; 2.6</td></tr><tr><td align="left">Oxygen saturation, %</td><td align="center">98 &#x000b1; 1</td><td align="center">97 &#x000b1; 1</td><td align="center">97 &#x000b1; 1</td><td align="center">97 &#x000b1; 1</td></tr><tr><td align="left">MAP, mmHg</td><td align="center">93 &#x000b1; 2</td><td align="center">92 &#x000b1; 3</td><td align="center">91 &#x000b1; 3</td><td align="center">91 &#x000b1; 3</td></tr></tbody></table><table-wrap-foot><p>*P &#x0003c; 0.05 vs. before oxygen administration. Values are means &#x000b1; SEM.</p></table-wrap-foot></table-wrap></sec><sec><title>Hyperoxic Chemoreflex Sensitivity</title><p>The hyperoxic CHRS values determined in controls were comparable to those obtained previously in healthy persons [<xref ref-type="bibr" rid="B11">11</xref>]. CHRS was significantly impaired in patients with ESRD (2.9 &#x000b1; 0.9 ms/mmHg, P &#x0003c; 0.05), as compared with controls (7.9 &#x000b1; 1.4 ms/mmHg; Figure <xref ref-type="fig" rid="F1">1</xref>). A chemoreflex sensitivity below 3 ms/mmHg was found in 8 ESRD patients and in 2 controls. No differences were observed in baseline clinical parameters between patients with and without a CHRS below 3 ms/mmHg. Comparisons of CHRS according to medication (alpha-blockers, beta-blockers, ca-antagonists, ACE-inhibitors/AT-II-antagonists) or history (hypertension, coronary artery disease) failed to reveal any significant difference between those patients.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Hyperoxic chemoreflex sensitivity (CHRS) is impaired in end-stage renal disease (ESRD) patients (n = 10) as compared with controls (n = 10)</bold>. Values are means &#x000b1; SEM.</p></caption><graphic xlink:href="2047-783X-14-S4-151-1"/></fig></sec><sec><title>Sympathetic Hyperacitivity Predicts Impaired Hyperoxic CHRS</title><p>The SDANN, as a marker of a relative predominance of sympathetic activity, correlated with the hyperoxic CHRS (r = 0.46; P &#x0003c; 0.01). On multiple regression analysis 24 h-Triangular index, RMSSD, and plasma norepinephrine levels were independent predictors of an impaired hyperoxic CHRS.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The present study demonstrates that sympathetic hyperactivity influences chemosensory function in ESRD resulting in an impaired hyperoxic CHRS. Our findings support previous reports showing that tonic activation of excitatory chemoreflex afferents contributes to increased systemic efferent sympathetic activity in patients with ESRD [<xref ref-type="bibr" rid="B6">6</xref>]. Herein, we have shown for the first time that plasma noradrenaline levels and HRV determine the chemosensory function in these patients. The present study indicates that the hyperoxic CHRS corroborates existing evidence for cardiac sympathetic hyperactivity in ESRD. Several reports demonstrated that cardiac autonomic control is disturbed in ESRD [<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B14">14</xref>]. Previous studies demonstrating increased plasma catecholamine levels, abnormal l-metaiodobenzylguanidine (MIBG) kinetics in the heart, and disturbed HRV in ESRD are in line with our findings and may in part explain the impaired CHRS in ESRD, while increased plasma catecholamines can potentiate the chemosensitivity towards oxygen [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. CHRS and HRV has been demonstrated to be predictors of ventricular tachyarrhythmias [<xref ref-type="bibr" rid="B10">10</xref>]. A combined short-term autonomic reflex testing including CHRS, HRV, and baroreflex sensitivity might improve the prognostic value of these functional modalities but was beyond the scope of the present study. Our results cannot be explained by recruitment of patients from different populations because the ESRD patients and controls were comparable in their demographic characteristics and medical history. This is important since CHRS is altered during heart failure [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B17">17</xref>], neurocardiogenic syncope [<xref ref-type="bibr" rid="B18">18</xref>], and can be influenced by medications likely to modulate cardiovascular autonomic function [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B19">19</xref>-<xref ref-type="bibr" rid="B21">21</xref>].</p><p>The mechanisms by which ESRD causes autonomic neuropathy are poorly understood. Direct and indirect measures of sympathetic activity agree that an adrenergic overdrive is common in ESRD. It is largely unknown how uremia affects different branches of the cardiovascular autonomic system like sensory afferent and efferent fibres. Chemoreceptor activation appears to contribute to the increased sympathetic drive of patients with ESRD. Currently, we do not know how sympathetic hyperactivity affects chemoreceptor function in ESRD.</p><p>There are some limitations of our study. HRV time-domain measures obtained by ambulatory ECG is confounded by daily activities, environment, circadian changes, and medications used. Although we tried to minimize these confounders by detailed exclusion criteria, the interference may still exist. For technical reasons we did not use the more sensitive but at least more invasive MIBG to characterize cardiac sympathetic control. In the current study we assessed chemosenory function in a relatively small number of patients due to the strict exclusion criteria. Finally, autonomic balance is maintained by multiple complex interacting reflex mechanisms, including arterial baroreflex, peripheral chemoreflex, central chemoreflex and pulmonary stretch reflex. Further investigations are needed to explore the exact mechanism of sympathetic chemosensory regulation in ESRD. Herein, we have demonstrated that sympathetic hyperactivity influences chemosensory function in ESRD resulting in an impaired hyperoxic CHRS.</p></sec><sec><title>Conflicts of interest</title><p>The authors declare that they have no competing interests.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Wirta</surname><given-names>O</given-names></name><name><surname>Pasternack</surname><given-names>A</given-names></name><name><surname>Mustonen</surname><given-names>J</given-names></name><name><surname>Laippala</surname><given-names>P</given-names></name><article-title>Renal and cardiovascular predictors of 9-year total and sudden cardiac mortality in non-insulin-dependent diabetic subjects</article-title><source>Nephrol Dial Transplant</source><year>1997</year><volume>12</volume><fpage>2612</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1093/ndt/12.12.2612</pub-id><pub-id pub-id-type="pmid">9430860</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Converse</surname><given-names>RL</given-names><suffix>Jr</suffix></name><name><surname>Jacobsen</surname><given-names>TN</given-names></name><name><surname>Toto</surname><given-names>RD</given-names></name><etal/><article-title>Sympathetic overactivity in patients with chronic renal failure</article-title><source>N Engl J Med</source><year>1992</year><volume>327</volume><fpage>1912</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1056/NEJM199212313272704</pub-id><pub-id pub-id-type="pmid">1454086</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Ligtenberg</surname><given-names>G</given-names></name><name><surname>Blankestijn</surname><given-names>PJ</given-names></name><name><surname>Oey</surname><given-names>PL</given-names></name><etal/><article-title>Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure</article-title><source>N Engl J Med</source><year>1999</year><volume>340</volume><fpage>1321</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1056/NEJM199904293401704</pub-id><pub-id pub-id-type="pmid">10219067</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Neumann</surname><given-names>J</given-names></name><name><surname>Ligtenberg</surname><given-names>G</given-names></name><name><surname>Klein</surname><given-names>II</given-names></name><name><surname>Koomans</surname><given-names>HA</given-names></name><name><surname>Blankestijn</surname><given-names>PJ</given-names></name><article-title>Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment</article-title><source>Kidney Int</source><year>2004</year><volume>65</volume><fpage>1568</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1111/j.1523-1755.2004.00552.x</pub-id><pub-id pub-id-type="pmid">15086894</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Hausberg</surname><given-names>M</given-names></name><name><surname>Kosch</surname><given-names>M</given-names></name><name><surname>Harmelink</surname><given-names>P</given-names></name><etal/><article-title>Sympathetic nerve activity in end-stage renal disease</article-title><source>Circulation</source><year>2002</year><volume>106</volume><fpage>1974</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000034043.16664.96</pub-id><pub-id pub-id-type="pmid">12370222</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Hering</surname><given-names>D</given-names></name><name><surname>Zdrojewski</surname><given-names>Z</given-names></name><name><surname>Krol</surname><given-names>E</given-names></name><etal/><article-title>Tonic chemoreflex activation contributes to the elevated muscle sympathetic nerve activity in patients with chronic renal failure</article-title><source>J Hypertens</source><year>2007</year><volume>25</volume><fpage>157</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1097/HJH.0b013e3280102d92</pub-id><pub-id pub-id-type="pmid">17143187</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Seals</surname><given-names>DR</given-names></name><name><surname>Johnson</surname><given-names>DG</given-names></name><name><surname>Fregosi</surname><given-names>RF</given-names></name><article-title>Hyperoxia lowers sympathetic activity at rest but not during exercise in humans</article-title><source>Am J Physiol</source><year>1991</year><volume>260</volume><fpage>R873</fpage><lpage>R878</lpage><pub-id pub-id-type="pmid">2035699</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Levey</surname><given-names>AS</given-names></name><name><surname>Bosch</surname><given-names>JP</given-names></name><name><surname>Lewis</surname><given-names>JB</given-names></name><name><surname>Greene</surname><given-names>T</given-names></name><name><surname>Rogers</surname><given-names>N</given-names></name><name><surname>Roth</surname><given-names>D</given-names></name><article-title>A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group</article-title><source>Ann Intern Med</source><year>1999</year><volume>130</volume><fpage>461</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">10075613</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Hennersdorf</surname><given-names>MG</given-names></name><name><surname>Hillebrand</surname><given-names>S</given-names></name><name><surname>Perings</surname><given-names>C</given-names></name><name><surname>Strauer</surname><given-names>BE</given-names></name><article-title>Chemoreflex sensitivity in chronic heart failure patients</article-title><source>Eur J Heart Fail</source><year>2001</year><volume>3</volume><fpage>679</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/S1388-9842(01)00189-1</pub-id><pub-id pub-id-type="pmid">11738219</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Hennersdorf</surname><given-names>MG</given-names></name><name><surname>Niebch</surname><given-names>V</given-names></name><name><surname>Perings</surname><given-names>C</given-names></name><name><surname>Strauer</surname><given-names>BE</given-names></name><article-title>Chemoreflex sensitivity as a predictor of arrhythmia relapse in ICD recipients</article-title><source>Int J Cardiol</source><year>2002</year><volume>86</volume><fpage>169</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/S0167-5273(02)00191-2</pub-id><pub-id pub-id-type="pmid">12419553</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Budeus</surname><given-names>M</given-names></name><name><surname>Hennersdorf</surname><given-names>M</given-names></name><name><surname>Perings</surname><given-names>C</given-names></name><article-title>Chemoreflex sensitivity among patients with paroxysmal atrial fibrillation</article-title><source>Z Kardiol</source><year>2003</year><volume>92</volume><fpage>558</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1007/s00392-003-0952-1</pub-id><pub-id pub-id-type="pmid">12883840</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Steinberg</surname><given-names>AA</given-names></name><name><surname>Mars</surname><given-names>RL</given-names></name><name><surname>Goldman</surname><given-names>DS</given-names></name><name><surname>Percy</surname><given-names>RF</given-names></name><article-title>Effect of end-stage renal disease on decreased heart rate variability</article-title><source>Am J Cardiol</source><year>1998</year><volume>82</volume><fpage>1156</fpage><lpage>8</lpage><comment>A10</comment><pub-id pub-id-type="doi">10.1016/S0002-9149(98)00580-3</pub-id><pub-id pub-id-type="pmid">9817506</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Tong</surname><given-names>YQ</given-names></name><name><surname>Hou</surname><given-names>HM</given-names></name><article-title>Alteration of heart rate variability parameters in nondiabetic hemodialysis patients</article-title><source>Am J Nephrol</source><year>2007</year><volume>27</volume><fpage>63</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1159/000099013</pub-id><pub-id pub-id-type="pmid">17259695</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Tory</surname><given-names>K</given-names></name><name><surname>Suveges</surname><given-names>Z</given-names></name><name><surname>Horvath</surname><given-names>E</given-names></name><etal/><article-title>Autonomic dysfunction in uremia assessed by heart rate variability</article-title><source>Pediatr Nephrol</source><year>2003</year><volume>18</volume><fpage>1167</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1007/s00467-003-1280-4</pub-id><pub-id pub-id-type="pmid">13680330</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Kurata</surname><given-names>C</given-names></name><name><surname>Uehara</surname><given-names>A</given-names></name><name><surname>Sugi</surname><given-names>T</given-names></name><etal/><article-title>Cardiac autonomic neuropathy in patients with chronic renal failure on hemodialysis</article-title><source>Nephron</source><year>2000</year><volume>84</volume><fpage>312</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1159/000045605</pub-id><pub-id pub-id-type="pmid">10754407</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Weil</surname><given-names>JV</given-names></name><name><surname>Byrne-Quinn</surname><given-names>E</given-names></name><name><surname>Sodal</surname><given-names>IE</given-names></name><name><surname>Kline</surname><given-names>JS</given-names></name><name><surname>McCullough</surname><given-names>RE</given-names></name><name><surname>Filley</surname><given-names>GF</given-names></name><article-title>Augmentation of chemosensitivity during mild exercise in normal man</article-title><source>J Appl Physiol</source><year>1972</year><volume>33</volume><fpage>813</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">4643864</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Hennersdorf</surname><given-names>MG</given-names></name><name><surname>Perings</surname><given-names>C</given-names></name><name><surname>Niebch</surname><given-names>V</given-names></name><name><surname>Hillebrand</surname><given-names>S</given-names></name><name><surname>Vester</surname><given-names>EG</given-names></name><name><surname>Strauer</surname><given-names>BE</given-names></name><article-title>Chemoreflexsensitivity in patients with survived sudden cardiac arrest and prior myocardial infarction</article-title><source>Pacing Clin Electrophysiol</source><year>2000</year><volume>23</volume><fpage>457</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1111/j.1540-8159.2000.tb00827.x</pub-id><pub-id pub-id-type="pmid">10793434</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="other"><name><surname>Meyer</surname><given-names>C</given-names></name><name><surname>Rana</surname><given-names>OR</given-names></name><name><surname>Saygili</surname><given-names>E</given-names></name><etal/><article-title>Hyperoxic chemoreflex sensitivity is impaired in patients with neurocardiogenic syncope</article-title><source>Int J Cardiol</source><year>2009</year></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Wenzel</surname><given-names>RR</given-names></name><name><surname>Allegranza</surname><given-names>G</given-names></name><name><surname>Binggeli</surname><given-names>C</given-names></name><etal/><article-title>Differential activation of cardiac and peripheral sympathetic nervous system by nifedipine: role of pharmacokinetics</article-title><source>J Am Coll Cardiol</source><year>1997</year><volume>29</volume><fpage>1607</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/S0735-1097(97)00095-8</pub-id><pub-id pub-id-type="pmid">9180126</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Wallin</surname><given-names>BG</given-names></name><name><surname>Sundlof</surname><given-names>G</given-names></name><name><surname>Stromgren</surname><given-names>E</given-names></name><name><surname>Aberg</surname><given-names>H</given-names></name><article-title>Sympathetic outflow to muscles during treatment of hypertension with metoprolol</article-title><source>Hypertension</source><year>1984</year><volume>6</volume><fpage>557</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.6.4.557</pub-id><pub-id pub-id-type="pmid">6378790</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Neumann</surname><given-names>J</given-names></name><name><surname>Ligtenberg</surname><given-names>G</given-names></name><name><surname>Oey</surname><given-names>L</given-names></name><name><surname>Koomans</surname><given-names>HA</given-names></name><name><surname>Blankestijn</surname><given-names>PJ</given-names></name><article-title>Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure</article-title><source>J Am Soc Nephrol</source><year>2004</year><volume>15</volume><fpage>2902</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1097/01.ASN.0000143471.10750.8C</pub-id><pub-id pub-id-type="pmid">15504943</pub-id></mixed-citation></ref></ref-list></back></article>